
Eptinezumab in episodic migraine:
A randomized, double-blind, placebo-controlled study (PROMISE-1).
Ashina M, Saper J, Cady R, Schaeffler BA, Bioni DM, Hirman J, et al.
Cephalalgia. 2020;40(3):241-254.

Eptinezumab for the prevention of chronic migraine:
Efficacy and safety throught 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study
Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J, et al.
J Headache Pain. 2020;21(1):120. doi: 10.1186/s10194-020-01186-3.